Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial symbols : LLY save search
Blacksmith Medicines Announces $3.3M in Funding from NIAID to Support Clinical Trial Manufacturing of Novel Antibiotic
Published: 2024-02-21 (Crawled : 15:00) - prnewswire.com
CYT | $3.02 2.65% 1M
|
Manufacturing
|
| O: -0.32%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -2.33%
H: 1.55%
C: 1.06%
trial funding
Vanda Pharmaceuticals announces the publication of an article on The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial
Published: 2024-01-25 (Crawled : 22:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -1.0%
H: 0.84%
C: 0.04%
VNDA | $4.57 -1.3% -1.31% 1.5M
|
Health Technology
|
| O: 2.72%
H: 0.53%
C: 0.53%
publication pharmaceuticals trial diabetic
Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting
Published: 2024-01-23 (Crawled : 17:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.51%
H: 0.37%
C: 0.32%
genetic association positive research meeting trial therapy
AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Published: 2024-01-16 (Crawled : 12:30) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.15%
H: 0.59%
C: -1.45%
erbitux first cell trial
Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA
Published: 2024-01-09 (Crawled : 00:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.65%
H: 0.69%
C: -0.73%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.0%
H: 0.53%
C: -2.19%
obesity first chinese key trial
Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China
Published: 2023-12-28 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: -1.32%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.08%
H: 0.81%
C: -0.19%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.52%
H: 0.72%
C: -0.34%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.35%
H: 1.07%
C: -0.27%
candidate tumors collaboration trial advanced china therapy
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
Published: 2023-12-18 (Crawled : 12:30) - globenewswire.com
PNT | $13.68 2.63% 0.15% 0
|
|
| O: -10.09%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.61%
H: 1.14%
C: 0.57%
LNTH | $65.19 1.21% 1.2% 580K
|
Health Technology
|
| O: -19.87%
H: 5.04%
C: -8.75%
positive cancer biopharma topline trial results
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial
Published: 2023-12-15 (Crawled : 12:30) - globenewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.39%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -4.44%
H: 0.0%
C: 0.0%
ACIU | $2.33 -2.1% -2.15% 320K
|
Health Technology
|
| O: -1.62%
H: 9.04%
C: 7.4%
disease active alzheimer’s immunotherapy trial
Sermonix Pharmaceuticals Announces Publication of ELAINE-1 and ELAINE-2 Trial Results in Annals of Oncology
Published: 2023-12-11 (Crawled : 20:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.61%
H: 0.0%
C: 0.0%
LGND | $70.87 1.4% 1.38% 150K
|
Health Technology
|
| O: 0.29%
H: 1.26%
C: 0.87%
publication pharmaceuticals trial results
BioAge Labs Announces Plans for Phase 2 Trial of First-in-Class Apelin Receptor Agonist BGE-105/Azelaprag Co-Administered With Tirzepatide for Treatment of Obesity, in Collaboration With Lilly’s Chorus Organization
Published: 2023-10-26 (Crawled : 00:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -1.68%
H: 0.0%
C: 0.0%
bge-105 agonist treatment collaboration trial tirzepatide
Therini Bio Announces Interim Results from the Phase 1 Trial of THN391 for the Potential Treatment of Dementia
Published: 2023-10-24 (Crawled : 14:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.84%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.77%
H: 0.0%
C: 0.0%
thn391 treatment dementia trial potential results
Lilly’s Mirikizumab Shows Long-Term Remission in Phase III Crohn’s Trial
Published: 2023-10-12 (Crawled : 15:30) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.97%
H: 0.0%
C: 0.0%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -1.87%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.54%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: 0.0%
trial
Lilly's Mirikizumab Helped Patients with Crohn's Disease Achieve Long-Term Remission in Phase 3 Trial
Published: 2023-10-12 (Crawled : 13:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.54%
H: 0.0%
C: 0.0%
disease trial
ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
Published: 2023-10-03 (Crawled : 10:00) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
ALXO M | $16.24 4.77% 4.56% 440K
|
Commercial Services
|
| O: 68.19%
H: 2.84%
C: -7.17%
aspen-06 positive cancer treatment trial results
Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)
Published: 2023-09-26 (Crawled : 13:00) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: 0.0%
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: 5.69%
H: 3.37%
C: -10.11%
fda sabizabulin respiratory trial agreement
Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate VERZENIO® (abemaciclib) in Combination with BBI-355 in Patients with CDK4 or CDK6 Amplified Solid Tumors
Published: 2023-09-19 (Crawled : 13:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.06%
H: 1.19%
C: 0.58%
bbi-355 verzenio tumors collaboration trial agreement
ADDF Statement on New Results from Donanemab's TRAILBLAZER-ALZ 2 Trial
Published: 2023-07-17 (Crawled : 16:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.0%
H: 0.26%
C: -0.51%
trial results
New England Journal of Medicine Publishes BRUIN Phase 1/2 Trial Data for Pirtobrutinib in BTK Inhibitor Pre-Treated Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Published: 2023-07-06 (Crawled : 13:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.55%
H: 0.97%
C: 0.02%
leukemia trial
Antibody-drug Conjugates Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain
Published: 2023-06-26 (Crawled : 21:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 2.15%
H: 1.18%
C: 0.43%
SRNE | $0.015 -8.85% 56K
|
Health Technology
|
| O: -1.0%
H: 4.2%
C: 1.3%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.82%
H: 0.02%
C: -0.85%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.17%
H: 0.0%
C: 0.0%
OMER | $3.04 -1.62% -1.64% 250K
|
Health Technology
|
| O: 0.19%
H: 2.22%
C: 1.76%
IMGN | News | $31.23 0.03% 49M
|
Health Technology
|
| O: 0.58%
H: 2.57%
C: 0.26%
companies pipeline trial
Sermonix Pharmaceuticals Announces Article Comparing ‘Traditional’ to ‘Just-in-Time’ Trial Enrollment Models Is Published in JCO Clinical Cancer Informatics
Published: 2023-06-26 (Crawled : 18:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.4%
H: 0.0%
C: -2.69%
LGND | $70.87 1.4% 1.38% 150K
|
Health Technology
|
| O: -0.3%
H: 1.85%
C: -0.84%
cancer pharmaceuticals trial
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.